

Glioblastoma, IDH-wildtype, with oligodendrocyte-like cells – a microscopic challenge

Gabriele Gaggero¹ , Giulio Fraternali Orcioni², Fabrizio Giordano², Valerio Gaetano Vellone¹

¹Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy

²S.C. Anatomia Patologica, A.O. Santa Croce e Carle, Cuneo, Italy




Figure 1. **A** – photomicrograph (haematoxylin-eosin stain, 40x), showing a neoplasm with oligodendrogloma-like aspects, i.e. round cells with clear perinuclear halos; **B** – photomicrograph (haematoxylin-eosin stain, 60x), where mitosis is evident; **C** – Immunohistochemistry for IDH R132H negative, indicating an IDH-wildtype profile (magnification: 40x)

A 71-year-old woman, who underwent surgery for a meningioma 13 years earlier, presented with an expansive lesion in the left cerebellar hemisphere at her last neuroradiological follow-up check, which was surgically excised. Microscopy showed a glial neoplasm (immunohistochemically positive for GFAP and Olig2) with: increased cellularity, atypia, mitosis and vascular proliferation. Noteworthy, was the presence of numerous round neoplastic cells with a clear perinuclear halo (fig. 1A–B), areas of ‘chicken-wire’ vascularization and micro-calcifications: these constitute the classic histologic features of oligodendrogloma (OG). However, this morphological hypothesis was not supported by the molecular investigations,

which instead showed a non-oligodendroglial lineage profile: IDH-wildtype by immunohistochemistry (fig. 1C) and 1p/19q non co-deleted (investigated by FISH method). On the basis of the integration of morpho-molecular data, the definitive diagnosis was therefore that of glioblastoma (GB), IDH-wildtype, with oligodendrocyte-like cells (GBO). GBO is a rare histological pattern of GB, reported in the latest World Health Organization classification of central nervous system tumours of 2021 [1], which should not be misdiagnosed as OG. Although both entities constitute forms of diffuse gliomas, distinguishing GBO from OG is not only a fine histological difference, but also and above all constitutes precise and important clinical-therapeutic information. Indeed, the two neoplasms differ in both their biological behaviour and prognosis, which are worse for GBO [1]. But even more important is the message that increasingly new differences are emerging in the molecular targets of medical therapy of the different types of glioma, some already approved and employed, others still undergoing clinical or laboratory studies [2].

References

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021; 23(8): 1231–1251, doi: 10.1093/neuonc/noab106, indexed in Pubmed: 34185076.
2. Muzyka L, Goff NK, Choudhary N, et al. Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies. *Int J Mol Sci.* 2023; 24(13), doi: 10.3390/ijms241310456, indexed in Pubmed: 37445633.

How to cite:

Gaggero G, Orcioni GF, Giordano F, Vellone VG. *Glioblastoma, IDH-wildtype, with oligodendrocyte-like cells – a microscopic challenge.* *NOWOTWORY J Oncol* 2024; 74: 157.

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.